Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-321 (Serclutamab Talirine) in EGFR-overexpressing advanced solid tumors
NCT03234712Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of serclutamab talirine in solid tumor (advanced stage) and glioblastoma (GBM), sponsored by AbbVie Inc. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 6 more. Started Oct 2017; status: completed.
02
Drugs
serclutamab talirine
03
Conditions
solid tumor (advanced stage)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03234712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03234712.